Product image of Leridip (Lercanidipine Hydrochloride) supplied by GNH India

Leridip

Active Ingredient:
Lercanidipine Hydrochloride
Origin:
EU

Leridip (Lercanidipine Hydrochloride)

Lercanidipine, the active ingredient in Leridip, is a calcium channel blocker presented as an oral tablet for systemic use. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure through vascular smooth‑muscle relaxation.

GNH India supplies Leridip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Manufacturer / TM Owner

Berlin-Chemie Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Leridip (l ercanidipine) is used to treat conditions related to elevated blood pressure.
  • Hypertension: reduces systolic and diastolic blood pressure to target levels.
  • Essential hypertension: provides long‑term blood pressure control.
  • Secondary hypertension (adjunct): assists in managing blood pressure when other causes are present.
  • Elderly hypertension: offers once‑daily dosing suitable for older patients.
  • Hypertensive patients requiring combination therapy: can be combined with other antihypertensives for additive effect.

How It Works

  • Lercanidipine selectively blocks L‑type calcium channels in vascular smooth‑muscle cells, inhibiting calcium influx. This leads to relaxation of arterial smooth muscle, resulting in vasodilation and a consequent reduction in peripheral vascular resistance and arterial blood pressure.

Side Effects

Leridip may cause several adverse reactions, ranging from mild to serious.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Flushing: transient warmth and redness.
  • Peripheral edema: swelling of ankles or feet.
  • Dizziness: especially upon standing.
  • Tachycardia: increased heart rate.
  • Palpitations: sensation of irregular heartbeat.

Serious or Rare Side Effects

  • Severe hypotension: marked drop in blood pressure.
  • Myocardial infarction: rare cardiac event.
  • Arrhythmias: abnormal heart rhythms.
  • Hepatic dysfunction: elevated liver enzymes.
  • Stevens‑Johnson syndrome: severe skin reaction.
  • Angioedema: swelling of face, lips, or throat.

Precautions & Warnings

  • Before initiating therapy with Leridip, consider the following precautions.
  • Monitor blood pressure: ensure adequate control and avoid excessive drops.
  • Assess hepatic function: adjust use in patients with liver impairment.
  • Use caution in the elderly: increased sensitivity to hypotensive effects.
  • Avoid abrupt discontinuation: taper to prevent rebound hypertension.
  • Review concomitant CYP3A4 inhibitors: may increase drug exposure.
  • Store at ambient temperature: keep below 25°C, protect from moisture and light.

Avoid Interactions

Leridip can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
  • Concurrent use with other potent antihypertensives: risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- Grapefruit juice: can modestly increase drug exposure.

  • Diuretics: may enhance electrolyte disturbances.
  • Beta‑blockers: may increase risk of bradycardia.
  • NSAIDs: may attenuate antihypertensive effect.
  • Antacids containing aluminum or magnesium: may affect absorption.

Frequently Asked Questions

Leridip contains lercanidipine, a calcium channel blocker that is prescribed to lower high blood pressure in adults. It helps achieve target blood‑pressure levels by relaxing arterial smooth muscle, making it a standard option for managing hypertension.

Lercanidipine selectively blocks L‑type calcium channels in vascular smooth‑muscle cells. By preventing calcium entry, it causes the muscles to relax, leading to vasodilation, reduced peripheral resistance, and a subsequent fall in arterial blood pressure.

The dosage of Leridip is individualized by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. Only a qualified health‑care professional should determine the appropriate dose.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a health‑care provider.

To request Leridip, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Leridip belongs to the dihydropyridine class of calcium channel blockers, offering once‑daily dosing and a favorable side‑effect profile compared with some older agents. Unlike ACE inhibitors or ARBs, it primarily induces vasodilation without affecting the renin‑angiotensin system.

Leridip tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid environments.

Leridip is taken orally, usually once daily, with or without food, as directed by a health‑care professional. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events, although rare, can include severe hypotension, myocardial infarction, arrhythmias, hepatic dysfunction, and life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Leridip is contraindicated in patients with known hypersensitivity to lercanidipine or other dihydropyridine calcium channel blockers, and in individuals with severe aortic stenosis or unstable angina. Clinicians should also exercise caution in patients with significant liver impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lercanidipine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT